These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1465353)

  • 1. [A phosphine-substituted diphosphonic acid (HMPD) for improved scintigraphic detection of bone lesions].
    Steinsträsser A; Schwarz A; Alexander C; Berberich R; Zimmer M
    Nuklearmedizin; 1992 Oct; 31(5):164-71. PubMed ID: 1465353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of lung metastases from osteosarcoma by scintigraphy using 99mTc-methylene diphosphonate.
    Hoefnagel CA; Bruning PF; Cohen P; Marcuse HR; van der Schoot JB
    Diagn Imaging; 1981; 50(5):277-84. PubMed ID: 6457735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases.
    Pauwels EK; Blom J; Camps JA; Hermans J; Rijke AM
    Eur J Nucl Med; 1983; 8(3):118-22. PubMed ID: 6220908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake and localization of 99mTc-methylene diphosphonate in mouse osteosarcoma.
    Nakashima H; Ochi H; Yasui N; Hamada H; Ono K
    Eur J Nucl Med; 1982; 7(12):531-5. PubMed ID: 6218993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography).
    Ghiron J; Volkert WA; Garlich J; Holmes RA
    Int J Rad Appl Instrum B; 1991; 18(2):235-40. PubMed ID: 2026500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
    Pauwels EK; Camps JA; Blom J; Hermans J; Kelly JD; Cumming SA; Blackburn GM; Rashid A
    Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of 99mTc-diphosphonates in newly formed bone matrix as a measure of bone lesion detectability.
    Schuemichen C; Krause T; Umbach G; Wolff T
    Nuklearmedizin; 1988 Feb; 27(1):8-11. PubMed ID: 3368337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.
    Coleman RE; Meier CA; Rubens RD; Fogelman I
    Nucl Med Commun; 1988 Jul; 9(7):481-5. PubMed ID: 3173907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scintigraphy with 99mTc-phosphonate and 67gallium in patients suspected of primary bone tumors.
    Edeling CJ
    Nuklearmedizin; 1982 Aug; 21(4):136-9. PubMed ID: 6959075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication.
    Buell U; Kleinhans E; Zorn-Bopp E; Reuschel W; Muenzing W; Moser EA; Seiderer M
    J Nucl Med; 1982 Mar; 23(3):214-7. PubMed ID: 6460854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New criteria for scintigraphic follow-up of bone metastases following radiotherapy. Results of functional scintigraphy using 99mTc-MDP].
    Knop J; Stritzke P; Langendorff G
    Nuklearmedizin; 1985 Dec; 24(5-6):238-43. PubMed ID: 4094901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical comparison of 99mTc-DPD and two 99mTc-MDP agents.
    Vorne M; Vähätalo S; Lantto T
    Eur J Nucl Med; 1983; 8(9):395-7. PubMed ID: 6226527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
    Kumar V; Kumar D; Howman-Giles RB; Little DG
    Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scintigraphic evaluation of primary bone tumors. Comparison of technetium-99m phosphonate and gallium citrate imaging.
    Simon MA; Kirchner PT
    J Bone Joint Surg Am; 1980 Jul; 62(5):758-64. PubMed ID: 6446566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-seeking properties of Tc-99m carbonyl diphosphonic acid, dihydroxy-methylene diphosphonic acid and monohydroxy-methylene phosphoinic acid: concise communication.
    Wang TS; Fawwaz RA; Johnson LJ; Mojdehi GE; Johnson PM
    J Nucl Med; 1980 Aug; 21(8):767-70. PubMed ID: 7400832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A radiopharmaceutical and clinical comparison of 99mTc-Sn-hydroxymethylene diphosphonate with 99mTc-Sn-hydroxyethylidene diphosphonate.
    Silberstein EB
    Radiology; 1980 Sep; 136(3):747-51. PubMed ID: 6773104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent.
    Degrossi OJ; Oliveri P; García del Río H; Labriola R; Artagaveytía D; Degrossi EB
    J Nucl Med; 1985 Oct; 26(10):1135-9. PubMed ID: 4045556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New bone-seeking agent: animal study of Tc-99m-incadronate.
    Shigematsu M; Shomi S; Iwao H; Ochi H
    Ann Nucl Med; 2002 Feb; 16(1):55-9. PubMed ID: 11922209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which diphosphonate for routine bone scintigraphy (MDP, HDP or DPD)?
    Frühling J; Verbist A; Balikdjian D
    Nucl Med Commun; 1986 Jun; 7(6):415-25. PubMed ID: 3748485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the usefulness of Technetium 99m-labeled ethylidene-1-hydroxy-1,1'-diphosphonic acid (EHDP) and methylene diphosphonic acid (MDP) of Polish production for the diagnosis of bone metastases in patients treated at the Oncology Center, Institute of Oncology in Warsaw 1979-1987].
    Kozłowicz-Gudzińska I; Rysińska A; Giwojno A
    Nowotwory; 1988; 38(3):161-4. PubMed ID: 3149728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.